Profile data is unavailable for this security.
About the company
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
- Revenue in USD (TTM)29.44bn
- Net income in USD8.51bn
- Incorporated1987
- Employees17.60k
- LocationGilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404-1147United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.gilead.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 123.70bn | 32.50k | 17.56 | 6.62 | 11.18 | 2.57 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Vertex Pharmaceuticals Inc | 12.00bn | 3.95bn | 124.83bn | 6.10k | 32.05 | 6.69 | 42.81 | 10.40 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | -- | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | -- | -- | 8.90 | 14.10 | 838.09 | 7.83 | -- | -- |
| Pfizer Inc | 62.58bn | 7.75bn | 156.81bn | 81.00k | 20.35 | -- | 11.26 | 2.51 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Gilead Sciences Inc | 29.44bn | 8.51bn | 192.28bn | 17.60k | 22.85 | 8.50 | 22.89 | 6.53 | 6.78 | 6.78 | 23.46 | 18.23 | 0.499 | 2.05 | 6.31 | -- | 14.42 | 8.03 | 18.05 | 9.82 | 78.84 | 78.01 | 28.91 | 18.13 | 1.31 | 36.91 | -- | 73.41 | 2.40 | 3.58 | 1,672.92 | 133.35 | -- | 3.04 |
| Amgen Inc | 36.75bn | 7.71bn | 198.80bn | 28.00k | 25.94 | 22.98 | 19.01 | 5.41 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 108.46m | 8.74% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 75.91m | 6.12% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 60.24m | 4.86% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 46.05m | 3.71% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 42.87m | 3.46% |
| Geode Capital Management LLCas of 31 Dec 2025 | 29.70m | 2.39% |
| Dodge & Coxas of 31 Dec 2025 | 26.28m | 2.12% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 25.31m | 2.04% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 24.42m | 1.97% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 24.02m | 1.94% |
